Company Update (NASDAQ:GILD): Gilead’s Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week Objective in Two Phase 3b Studies

[Business Wire] – Gilead Sciences, Inc. today announced that two Phase 3b switch studies evaluating Odefsey® for the treatment of HIV-1 infection met their primary objectives. Read more on this. , currently valued at $ecting to http://finance.ya, finished yesterday at $. During the trading session, GILD traded between $ and has traded between $ over the past 12 months. Gilead (GILD) shares are currently priced at x this year’s forecasted earnings, which makes them relatively inexpensive compared to the industry’s x earnings multiple for the same period. In a review of the consensus earnings estimate this quarter, 0 sell-side analysts are looking at $ per share, which would be $0.00 worse than the year-ago quarter and a $0.00 sequential decrease. The full-year EPS estimate is $ which would be a $0.00 worse than last year’s full-year earnings. The quarterly earnings estimate is predicated on a consensus revenue forecast of $0.00 . If reported, that would be a 0.00% decrease over the year-ago quarter. In terms of ratings, d GILD from to (/fin). Previously, d GILD from to . Given all the information above, we should disclose to readers that the average price target is $, which is 0.00% below than it opened this morning. See more in (NASDAQ:GILD) Similar Articles: Stock Update (NASDAQ:GILD): European Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV Stock Update (NASDAQ:GILD): U.S. Food and Drug Administration Approves Gilead’s Second TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection Stock Update (NASDAQ:GILD): European Medicines Agency Validates Gilead’s Marketing Application for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B